Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ding! ding! ding! We have a winner!!!
Any reason you left out the comparison of the share count for the 2 companies?
Which begs the question: How much wire can they produce in the next 3 months?
Let's hope 2012 staements are a primer for 2013. 'Til then, yawn.
yup. that's a serious ass whupping this time 'round. wow!
I'll sell the MM my 261 shares for $45!
lol. I appreciate the portfolio polish, but let's hope there's some real action with this shell soon. It's been idle long enough.
I just dusted off my 261 shares still lurking in the dark corners of my portfolio. No need to sell here. Let's hope for some positive action in the near future.
TGTX up .48 (13%) to close at $4.09
Catalysts still looming in September. PP still $6.15 a share. Company unaware of reason for recent plunge.
GLTA still holding.
I'll sell you my shares for $3.45 today!! lol.
Lots of placements at .80 over the years, so not much is gonna happen til those folks are happy with their ROI.
No surprise to me on the current PPS- Potash prices suck now, AAA has accomplished a lot, but still has some huge hurdles to overcome....like raising better than 1/2 billion dollars to get their project off the ground. There's nothing to spark up the PPS between now and at least q1 2014, when Keraltas said to check back in for news about financing. I hope he's right. They've already had to back up forecast production by a year, so getting the shovels working on the new mine asap would be a big plus.
Other than the year delay in production, management has executed quite well. If you liked it at .93.........
I added to my TGTX today- I don't think the recent seller was any of the whales who ponied up $6.15 a share.
Good to see the company issue a PR today to calm the rumor mongers.
I also expect the ASH results to be positive. The company mentioned that they hadn't seen any adverse effects from the dosages that were used in the 2 studies to be released, so we shall see.
thx. cornered the baggy waaayyyyy too soon on that one.
noticed your refg has dropped into the low .20's.....you firing that one up again?
TGTX
Taking advantage of the down market day and the big fall off in PPS to open a position in TGTX. Shares have tumbled over the past week and the bottom might not be in yet, but there's lots of positives for this company before the end of the year
-recently sold 6,500,000 shares at $6.15, including fully subscribed over allotment of 855,000 shares
- 2 recent FDA Orphan Drug designations
- 2 phase 1/2 results to be presented at ASH in December 2013
- 4.3% short position
- 33 million shares outstanding
ATRS- I added today on the drop at 4.24. PDUFA is coming up, their application for Otrexup uses methotrexate, already heavily prescribed for arthritis.
Just a question of whether the FDA will approve the ATRS self-injection technology.
Thanks for the PHOT hit! Cashed out my baggy at .044 for a 17% profit. Great sector!
scraped a 12% resin hit from PHOT. Not much in the chamber to start with, but now I can get salsa with the bag of doritos.
Still a sticky green sector with lots of momo.
You still dealing REFG when it dips?
And years from now, when massive health care costs make voluntary euthanasia politically attractive, the tinman's legacy will surface once again and he'll be seen as prophetic, a pioneer for those of us who want control of our own destinies but can find little useful and rational information about what is currently a taboo subject.
I live in Sydney. The Aussie economy has nothing to do with elections. Australia is a flea, feeding away on China's ass. When that dries up, so will the Australian economy.
Twisted some sticky green REFG profits into PHOT....just a pinny, not a big fat Bob Marley.....if the company lays off the selling, it'll fire up nicely!
Great sector, what with Holder calling off the federal sniffing dogs.
cashed my REFG last week at .54 from a .36 initial hit. all proceeds going to pizza
lol. that's what I thought. A JV by any other link is still a JV.....NOT!!
We're all hoping the news is true and will break very soon, there ain't no JV yet. At least that AAA.TO has pr'ed
link to the JV please?
Let's get to that press release first. Nothing on the AAA website at this time.
GLTY. You're certainly a strong advocate of all your positions and an entertaining read, which counts for a lot on the message board circuit!
LOL, that's what they said about ENRON when it plunged from $80 to $8 a share.
this is dead money until the next q
Yup, hard to argue that. Unlike other P&Ds, they actually have a product that sells and has a niche in the kidney care market.
At .07 a share, the dilution required to raise any reaonable amount of money would kill the share structure.....not to mention every time it pops, the selling gets ferocious and relentless.
Last q it ran to .18 before tumbling back. Company promised a PR about the phase 3 #'s....hasn't happened yet.
And they'll certainly need to raise $$ soon.
I'm hoping that the previous 8K points to a sale, a partner or some help getting their product approved. It's going tp be hard for them to go it alone.
Lentinman- you crazy diamond.
What an amazing web site, what an amazing guy.
TEXC any news on the 2nd hole? Company indicated that this was going to start happening during the summer.
That's wonderful news! Hopefully their youth and strength and bring them to a full recovery!
MACK
from Mike Havrilla: The major risk factor for MACK includes expected failure for several Phase II clinical trials for MM-121 as previously reported and updated in the recent prospectus filing. I believe this is mostly a headline risk since most of the bad news should already be reflected in stock unless the drug fails in every ongoing Phase II trial.
This is a stock which needs little reason to get beat up any more, but it sounds like more reasons might be a comin'.....
BSTC out with a strong q:
EPS of .15 vs .10 a year ago (fully diluted)
Revenue up 26%
PDUFA September 6 for Peyronie's Disease
Multiple catalysts in the 2nd half of 2013
Low float and AUXL footing the bills
finance.yahoo.com/news/biospecifics-technologies-corp-reports-second-113000459.html
BSTC
another small floater. profitable. DD post here:
investorshub.advfn.com/boards/read_msg.aspx?message_id=90627663&txt2find=bstc
Love the biz model- few employess, another company AUXL, does all the selling and PR.
BSTC reporting on Thursday. Big volume day today- over 50k!!!
BSTC- fully agree that this is one of the best risk/reward PDUFA plays near term. Volume lately has been minisucle, but that'll change when folks connect BSTC with AUXL.
Highlights from the BSTC 10 May CC:
-We expect to report top line data from both the Phase II human lipoma trial and Chien-804 in canine lipoma in the second half of 2013.
-Data (for frozen shoulder) showed statistically significant improvements from baseline compared to control group in forward flexion and pain and function in two of the doses. There were no drug-related serious adverse events reported and all treatment-related adverse events were consistent with XIAFLEX use in other approved and potential indications. Most importantly, the data support progression into the next stage of development which Auxilium expects to initiate in the second half of 2013.
-Plans to launch XIAFLEX in Canada in Q2 2013
-We were pleased to announce this past quarter that the Journal of Urology electronically published data from the Peyronie’s Disease Phase III IMPRESS trial. If approved, XIAFLEX is expected to be the first and only biological therapy indicated for the treatment of Peyronie’s Disease. PDUFA date September 6
-The XIAFLEX pipeline is abundant with one indication on the market, another awaiting potential US approval and several more in clinical testing.
-Q1 2013 was $4.0 million compared to $2.6 million for the same period in 2012.and net income was $1.4 million for Q1 2013 or $0.21 per basic share and $0.19 per diluted share compared to a net income of $0.7 million or $0.12 per basic and $0.11 per diluted share for the same period in 2012
-As of March 31, 2013, we had cash and cash equivalents and investments of $12.2 million compared to $8.5 million as of December 31, 2012.
Last week, AUXL reported Global XIAFLEX revenue grew to $18.9 million with our U.S. XIAFLEX revenue of $15 million increasing 26% over the second quarter of last year.
AUXL CC transcript is worth a read- they clearly have big plans for XIAFLEX as the recent deal with Sobi demonstrates.
seekingalpha.com/article/1596982-auxilium-pharmaceuticals-management-discusses-q2-2013-results-earnings-call-transcript?source=yahoo
BSTC has a share buyback program in place. 6.35 million shares outstanding with a tiny float of 4.24 million. Institutions hold almost 40%, insiders the same.
BSTC CC this Thursday 8 August at 8:30 AM to discuss 2nd quarter results.
ONCS press release hits the wires:
OncoSec Medical Presents Positive Immune Response Data from Phase II Study at the 8th World Congress of Melanoma
Data Confirms the Systemic Effects of DNA IL-12 Administered Locally with Electroporation
Jul. 22, 2013 / Updated: Monday, Jul. 22, 2013 06:14 AM
SAN DIEGO --
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announced interim immune response data from the company’s Phase II study of ImmunoPulse in patients with metastatic melanoma. Findings showed that OncoSec’s ImmunoPulse demonstrated a significant change in tumor immunity following treatment with DNA IL-12 and electroporation. Dr. Adil Daud, principal investigator at the University of California San Francisco, presented the data at the 8th World Congress of Melanoma in Hamburg, Germany.
Blood samples taken at baseline (Day 1) and Day 90 from subjects treated with ImmunoPulse were analyzed. Changes in activated T-cells and regulatory T-cells were quantified. At Day 90 following treatment, it was demonstrated that there was a significant decrease in circulating “exhausted” CD8/PD-1+ (p=0.0017) and CD8/CD69+ (p=0.008) T-cells. PD-1 is expressed in activated exhausted T cells, and blocking PD-1 is an emerging treatment modality for multiple cancers including melanoma. These results demonstrate that plasmid delivery of interleukin-12 (IL-12) can also result in a decrease in exhausted T-cells, which may lead to improvement in clinical outcomes for patients treated with ImmunoPulse.
In addition to changes in circulating T-cells, an increase in NK cell frequency and activation was also observed from baseline. It was also demonstrated that antigen-specific T-cell responses to melanoma were increased with DNA IL-12 while other antibody responses were modulated and appeared to narrow over time. These data confirm the systemic effects of DNA IL-12 administered locally with electroporation.
Punit Dhillon, President and CEO of OncoSec, said: “We are encouraged by these immune data, since they highlight a potential mechanism of action for ImmunoPulse, and demonstrate the biologic activity of this therapy after only a single cycle of treatment.”
Dr. Daud commented: “The statistical significance of these data is impressive and confirms our understanding of the mechanism of action of IL-12. We look forward to understanding further if these changes in immune responses also correlate with positive clinical outcomes. These data will be shared later on this year.”
OncoSec recently announced completion of enrollment for its Phase II melanoma trial. Previously, the company announced that ImmunoPulse demonstrated clinical benefit in both locally treated and untreated distant melanoma lesions, and that the therapy appeared to be safe and well-tolerated, after an interim analysis of safety and efficacy of the first 13 patients.
About the Phase II ImmunoPulse Study
A total of 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma have been enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle consists of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients are moved to the follow-up phase of the study and will be followed for up to five years for safety.
About Melanoma
Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the US are diagnosed in a year, resulting in approximately 10,000 deaths. Melanoma originates in melanocytes, the cells that produce the pigment melanin that colors our skin, hair, and eyes. The majority of melanomas are black or brown, but often they can also be skin-colored, pink, red, purple, blue or white. Currently, there remain few treatment options for patients with late-stage metastatic disease that can extend survival for the broad population.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
______
I emailed that exact question to the company a few weeks ago as they had promised an update on the trial. No response.
ONCS: company's electroporation tech is lisensed from INO. Hopefully the phase 2 results will show the same promise as the recent INO press release.
28 million dollar valuation for ONCS should correct nicely if phase 2 results show similar potential to INO.
Wish the company had been a littler less vague about the release date for these results. Hard to have a run-up if people don't know the exact date for news.
Congrats on a tight finish. And thanks SSkillz for yet another great contest.